E
ABMD

Ergoteles’s Abiomed Inc ABMD Stock Holding History

Ergoteles’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,475
Closed -$365K – 2184
2022
Q2 		$365K Buy
+1,475
New +$398K 0.01% 1004
2021
Q4 		– Sell
-7,302
Closed -$2.38M – 1728
2021
Q3 		$2.38M Buy
7,302
+6,302
+630% +$2.13M 0.09% 235
2021
Q2 		$312K Buy
+1,000
New +$307K 0.01% 1050

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Ergoteles's ABMD Position: Q3 2022 in Review

Ergoteles sold out of Abiomed Inc (ABMD) in Q3 2022, closing a stake of 1,475 shares — an estimated $365K sold.

Ergoteles first reported a position in ABMD in Q2 2021 and held it in 3 quarters. The position peaked at $2.38M in Q3 2021. 517 funds tracked by Wall St. Rank hold ABMD as of Q3 2022.

  • Ergoteles reported no remaining Abiomed Inc position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 1,475 Abiomed Inc shares in Q3 2022, an estimated $365K.
  • Ergoteles first reported a position in Abiomed Inc in Q2 2021 and held it in 3 quarters.
  • Ergoteles's Abiomed Inc position peaked at $2.38M in Q3 2021.
  • 517 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.